Literature DB >> 12120183

Update on medical management of inflammatory bowel disease: ulcerative colitis.

S B Hanauer1.   

Abstract

Significant advances have been made regarding our understanding of the etiopathogenesis of inflammatory bowel disease. This review focuses on the most recent applications of medical therapy for ulcerative colitis. Therapeutic approaches continue to evolve regarding inductive and maintenance strategies with oral and topical aminosalicylates, systemic and non-systemic corticosteroids, and cyclosporine and alternative immunomodulators. As further investigations continue to discern microbiological and immunoinflammatory targets, future therapies may include both probiotics and novel biological agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12120183

Source DB:  PubMed          Journal:  Rev Gastroenterol Disord        ISSN: 1533-001X


  3 in total

1.  Effects of probiotic on intestinal mucosa of patients with ulcerative colitis.

Authors:  Hai-Hong Cui; Cun-Long Chen; Ji-De Wang; Yu-Jie Yang; Yong Cun; Jin-Bao Wu; Yu-Hu Liu; Han-Lei Dan; Yan-Ting Jian; Xue-Qing Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

2.  Ameliorative effects of sodium ferulate on experimental colitis and their mechanisms in rats.

Authors:  Wei-Guo Dong; Shao-Ping Liu; Bao-Ping Yu; Dong-Fang Wu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

3.  A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis.

Authors:  Mark Lamet
Journal:  Dig Dis Sci       Date:  2010-07-30       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.